First Trust Direct Indexing’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-6,368
Closed -$365K 389
2024
Q3
$365K Sell
6,368
-196
-3% -$11.2K 0.02% 656
2024
Q2
$344K Buy
6,564
+1,405
+27% +$61.6K 0.02% 609
2024
Q1
$210K Sell
5,159
-494
-9% -$18.5K 0.02% 717
2023
Q4
$209K Buy
+5,653
New +$213K 0.02% 701
2023
Q3
Sell
-11,371
Closed -$410K 716
2023
Q2
$410K Buy
11,371
+3,830
+51% +$131K 0.05% 464
2023
Q1
$288K Buy
7,541
+129
+2% +$6.05K 0.03% 551
2022
Q4
$422K Buy
7,412
+182
+3% +$9.32K 0.06% 420
2022
Q3
$286K Hold
7,230
0.04% 480
2022
Q2
$318K Sell
7,230
-197
-3% -$8.52K 0.04% 457
2022
Q1
$296K Buy
7,427
+911
+14% +$32.5K 0.04% 508
2021
Q4
$262K Buy
6,516
+41
+0.6% +$1.53K 0.03% 528
2021
Q3
$263K Sell
6,475
-1,071
-14% -$44.8K 0.04% 514
2021
Q2
$343K Buy
7,546
+2,516
+50% +$111K 0.05% 430
2021
Q1
$210K Buy
5,030
+308
+7% +$14.1K 0.06% 368
2020
Q4
$202K Buy
+4,722
New +$170K 0.05% 351

Other funds holding HALO

First Trust Direct Indexing's HALO Position: Q4 2024 in Review

First Trust Direct Indexing sold out of Halozyme (HALO) in Q4 2024, closing a stake of 6,368 shares — an estimated $365K sold.

First Trust Direct Indexing first reported a position in HALO in Q4 2020 and held it in 15 quarters. The position peaked at $422K in Q4 2022. 508 funds tracked by Wall St. Rank hold HALO as of Q4 2024.

  • First Trust Direct Indexing reported no remaining Halozyme position as of Q4 2024 after selling out during the quarter.
  • First Trust Direct Indexing sold 6,368 Halozyme shares in Q4 2024, an estimated $365K.
  • First Trust Direct Indexing first reported a position in Halozyme in Q4 2020 and held it in 15 quarters.
  • First Trust Direct Indexing's Halozyme position peaked at $422K in Q4 2022.
  • 508 funds tracked by Wall St. Rank held Halozyme as of Q4 2024.

Based on First Trust Direct Indexing's 13F filing for Q4 2024.